98 related articles for article (PubMed ID: 4000312)
21. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
23. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
[TBL] [Abstract][Full Text] [Related]
24. Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer.
Murphy LC; Hilsenbeck SG; Dotzlaw H; Fuqua SA
Clin Cancer Res; 1995 Feb; 1(2):155-9. PubMed ID: 9815968
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy.
Takei H; Horiguchi J; Maemura M; Koibuchi Y; Oyama T; Yokoe T; Iino Y; Morishita Y
Oncol Rep; 2002; 9(2):375-8. PubMed ID: 11836611
[TBL] [Abstract][Full Text] [Related]
26. Timing of breast cancer surgery within the menstrual cycle: tumor proliferative activity, receptor status and short-term clinical outcome.
Mangia A; De Lena M; Barletta A; Marzullo F; Attolico M; Stea B; Petroni S; Labriola A; Cellamare G; Digiesi G; Altieri R; Schittulli F; Paradiso A
J Exp Clin Cancer Res; 1998 Sep; 17(3):317-23. PubMed ID: 9894769
[TBL] [Abstract][Full Text] [Related]
27. The associations of obesity, lymph node status and prognosis in breast cancer patients: dependence on estrogen and progesterone receptor status.
Maehle BO; Tretli S; Thorsen T
APMIS; 2004 Jun; 112(6):349-57. PubMed ID: 15511272
[TBL] [Abstract][Full Text] [Related]
28. Progesterone receptor status provides predictive value for adjuvant endocrine therapy in older estrogen receptor-positive breast cancer patients.
Yu KD; Liu GY; Di GH; Wu J; Lu JS; Shen KW; Shen ZZ; Shao ZM
Breast; 2007 Jun; 16(3):307-15. PubMed ID: 17293115
[TBL] [Abstract][Full Text] [Related]
29. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
30. [Hormone receptors and breast cancer prognosis].
Saez S; Pichon MF
Pathol Biol (Paris); 1983 Dec; 31(10):801-8. PubMed ID: 6366701
[TBL] [Abstract][Full Text] [Related]
31. Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
Chang J; Powles TJ; Allred DC; Ashley SE; Makris A; Gregory RK; Osborne CK; Dowsett M
Clin Cancer Res; 2000 Feb; 6(2):616-21. PubMed ID: 10690547
[TBL] [Abstract][Full Text] [Related]
32. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
33. The oestrogen-progesterone receptor ratio: an indicator of breast cancer evolution.
Cherubini M; Baxa P; Guarino G
Chir Ital; 2002; 54(4):423-8. PubMed ID: 12239750
[TBL] [Abstract][Full Text] [Related]
34. Prediction of recurrence for advanced breast cancer. Traditional and contemporary pathologic and molecular markers.
Masood S
Surg Oncol Clin N Am; 1995 Oct; 4(4):601-32. PubMed ID: 8535901
[TBL] [Abstract][Full Text] [Related]
35. Adenocarcinoma of the cervix. Expression and clinical significance of estrogen and progesterone receptors.
Fujiwara H; Tortolero-Luna G; Mitchell MF; Koulos JP; Wright TC
Cancer; 1997 Feb; 79(3):505-12. PubMed ID: 9028361
[TBL] [Abstract][Full Text] [Related]
36. Factors associated with prognosis in human breast cancer. I. Predictors for rate of evolution and relapse.
Lage A; Rodriguez M; Pascual MR; Diaz JW; Fernandez L
Neoplasma; 1983; 30(4):475-83. PubMed ID: 6888610
[TBL] [Abstract][Full Text] [Related]
37. [Metastatic breast cancers: comparison of the prognostic significance and the sensitivity to chemotherapy according to the presence of estradiol and progesterone receptors].
Pouillart P; Madgelenat H; Jouve M; Palangie T; Garcia-Giralt E; Bretaudeau B; Polijcak M; Asselain B
Bull Cancer; 1982; 69(5):461-7. PubMed ID: 7165808
[TBL] [Abstract][Full Text] [Related]
38. [Prognosis prediction of S-phase fraction and p53, c-erbB-2, estrogen receptor, progesterone receptor in axillary node-negative breast cancer].
Zhang S; Yuan Y; Wang X
Zhonghua Wai Ke Za Zhi; 1997 Aug; 35(8):475-7. PubMed ID: 10678068
[TBL] [Abstract][Full Text] [Related]
39. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
[TBL] [Abstract][Full Text] [Related]
40. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.
Dowsett M; Allred C; Knox J; Quinn E; Salter J; Wale C; Cuzick J; Houghton J; Williams N; Mallon E; Bishop H; Ellis I; Larsimont D; Sasano H; Carder P; Cussac AL; Knox F; Speirs V; Forbes J; Buzdar A
J Clin Oncol; 2008 Mar; 26(7):1059-65. PubMed ID: 18227529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]